CalciMedica begins Phase I trials for CRAC channel inhibitor

US-based bio-pharmaceutical company CalciMedica has initiated the Phase I safety studies in healthy volunteers of a new calcium release-activated calcium (CRAC) channel inhibitor, CM4620, for treating acute pancreatitis.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news